Clinical trials: Carcinoma Breast
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma
Optimizing Treatment of Stage IV Breast Cancer Through Real-Time Disease Monitoring
This study evaluates if blood tests can detect changes in disease status during treatment for stage IV breast cancer. Information from this study may help researchers learn more about metastatic breast cancer and how to optimize…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
- Trial name
- NCT04906369
- Testing
- Biospecimen Collection
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Mayo Clinic
Metastatic Breast Cancer
A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
This was a multi-institutional, open-label, single-arm, Phase II study of trastuzumab emtansine (T-DM1) administered by intravenous (IV) infusion to patients with human epidermal growth factor receptor 2 (HER2)-positive…
- Trial name
- NCT00509769
- Testing
- Trastuzumab emtansine [Kadcyla]
- Where
- 40 sites in United States
- Volunteers
- 112 people
- Sponsor
- Genentech, Inc.
Breast Cancer Screening
Application of CfDNA Methylation Detection in Auxiliary Diagnosis of Breast Cancer
The purpose of this study is to construct an auxiliary diagnostic model for breast cancer by methylation markers. The study will collect blood and tissue samples from participants with breast cancer and benign disease for…
- Trial name
- NCT06876610
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Geneplus-Beijing Co. Ltd.
Breast Cancer
An Indirect Treatment Comparison of the Effectiveness of Ribociclib Combined With Non-steroidal Aromatase Inhibitors vs. Tamoxifen for the Adjuvant Treatment of Premenopausal Women With Hormon Receptor-positive, HER2-negative Early Breast Cancer
The purpose of this indirect treatment comparison (ITC) was to generate comparative evidence on the effectiveness and safety in premenopausal women of ribociclib+Non-steroidal Aromatase Inhibitor (NSAI)+Ovarian Function…
- Trial name
- IRINA (NCT07072013)
- Testing
- ribociclib
- Where
- Germany
- Volunteers
- 1,937 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer, Endocrine Therapy
Relationship Between Body Composition, Food Consumption, and Micro and Macronutrients With Gene Expression in Breast Cancer
The protocol involves measurement of 25 hidroxy vitamin D, gene expression of cytochrome and vitamin D receptor , endoxifen, tamoxifen, exemestane, and other metobolites related to nutrition and endocrine metabolism.
- Conditions
- Breast Cancer, Endocrine Therapy, Endocrine Therapy Adverse Reaction, Vitamin D Deficiency
- Trial name
- NUTRIBREAST (NCT04389424)
- Testing
- Tamoxifen, Exemestane, Anastrozole
- Where
- Mexico
- Volunteers
- 300 people
- Sponsor
- Instituto Jalisciense de Cancerologia
Breast Cancer
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
This research is to evaluate the effectiveness of Talazoparib as a potential treatment for metastatic breast cancer with a BRCA 1 or BRCA 2 mutation.
- Trial name
- NCT03990896
- Testing
- Talazoparib
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Massachusetts General Hospital
Margin Assessment, Breast Cancer
Spectral Cancer Tissue Recognition - I
This analytical performance study aims to validate the SPCTRone system for use in breast conserving surgery of breast cancer patients.
- Trial name
- SPCTR-I (NCT07459062)
- Where
- 2 sites in Netherlands
- Volunteers
- 100 people
- Sponsor
- SPCTR
Breast Cancer
Nanogen Pegfilgrastim (Pegcyte) PK/PD Clinical Study in Breast Cancer Patients
Breast cancer patients scheduled to receive myelosuppressive chemotherapy (AC regimen) will be enrolled in this study. Eligible patients receive single SC injection of pegcyte or neulastim 24 hours after administration of…
- Trial name
- NCT03376503
- Testing
- Pegfilgrastim
- Where
- Vietnam
- Volunteers
- 24 people
- Sponsor
- Nanogen Pharmaceutical Biotechnology Joint Stock Company
Breast Cancer
Multi-Beam Intensity-Modulated Radiation Therapy for Node-Positive Breast Cancer
This study is being performed to understand the safety of a new radiation treatment called "Multi-Beam Intensity Modulated Radiation Therapy" ( IMRT).
- Trial name
- NCT01127373
- Testing
- Multi-Beam Intensity-Modulated Radiation Therapy, BreastQ questionnaire-
- Where
- 7 sites in United States
- Volunteers
- 116 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Breast Cancer
A Pilot Study of a Micro-Organosphere Drug Screen Platform to Lead Care in Advanced Breast Cancer
The purpose of this study is to assess the feasibility of generating patient derived micro-organospheres (PDMO) from patients with advanced breast cancer to determine sensitivity to the most common forms of chemotherapy used in…
- Trial name
- NCT04655573
- Testing
- Breast Cancer Tumor Resection
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Duke University
Estrogen Receptor Negative, Estrogen Receptor Positive
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer
This randomized phase III trial studies the side effects and how well different chemotherapy regimens with or without bevacizumab work in treating patients with stage IIIC or stage IV breast cancer.
- Conditions
- Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, HER2/Neu Positive
- Trial name
- NCT00785291
- Testing
- Bevacizumab, Ixabepilone, Laboratory Biomarker Analysis
- Where
- 704 sites in United States, Puerto Rico
- Volunteers
- 799 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Chemotherapy Effect
Chidamide in Combination With Vincristine Metronomic Chemotherapy for Advanced Triple-negative Breast Cancer
The mechanism of action of cidabenamide and the advantages of vincristine metronomic chemotherapy make it possible to combine the two drugs.
- Trial name
- NCT05747313
- Testing
- Chidamide
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Breast Cancer
Peer Navigator Education in Improving Survivorship Care in African American Breast Cancer Survivors
This randomized clinical trial studies peer navigator education in improving survivorship care in African American breast cancer survivors.
- Trial name
- NCT01450020
- Testing
- educational intervention, questionnaire administration, counseling intervention
- Where
- United States
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Triple Negative Breast Cancer, Endometrial Cancer
ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma
Background: The new drug ONC201 have been shown to kill breast cancer and endometrial cancer cells in the laboratory. The exact mechanism of action is not completely clear yet, but the ONC201 destroys the mitochondria inside the…
- Conditions
- Triple Negative Breast Cancer, Endometrial Cancer, Hormone Receptor Positive, HER2 Negative Breast Cancer
- Trial name
- NCT03394027
- Testing
- ONC201
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Menopause, Normal Physiology
Premenopausal Hormone Concentrations in a Population of Women at Very Low Risk of Breast Cancer
Background: Incidence of breast cancer is very low in Mongolia (6.6/100,000), especially in rural areas. Over the past 15 years, there has been considerable economic growth in Mongolia, resulting in migration to urban centers…
- Trial name
- NCT00860886
- Where
- Mongolia
- Volunteers
- 412 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Paravertebral Block for Breast Surgery
The effect of paravertebral block in combination with general anaesthesia is studied in a double blind fashion.
- Trial name
- NCT00131170
- Testing
- paravertebral block
- Where
- Denmark
- Volunteers
- 90 people
- Sponsor
- University of Aarhus
Breast Cancer, HER2-positive Breast Cancer
HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission
Thie purpose of this study is to find out whether a personalized treatment approach-using a series of ctDNA tests along with standard imaging scans to help decide when to step up (escalate) or decrease (de-escalate) sequential…
- Conditions
- Breast Cancer, HER2-positive Breast Cancer, Breast Cancer Stage IV
- Trial name
- NCT07459673
- Testing
- Personalis NeXT Personal, Natera Signatera, fam-trastuzumab deruxtecan-nxki (T-DXd)
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hormone Receptor Positive, HER2-low or HER2-ultralow
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
The primary purpose of the study is to assess the safety, tolerability, and anti-tumor activity of HER3-DXd and T-DXd in the combination dosing regimens in participants with hormone receptor positive, HER2-low or HER2-ultralow…
- Conditions
- Hormone Receptor Positive, HER2-low or HER2-ultralow, Unresectable or Metastatic Breast Cancer
- Trial name
- NCT07701941
- Testing
- Patritumab deruxtecan, Trastuzumab deruxtecan
- Where
- 72 sites in United States, Belgium and 6 more
- Volunteers
- 220 people
- Sponsor
- Daiichi Sankyo
Breast Cancer, Metastatic Breast Cancer
Promoting Resilience in Women With Breast Cancer (PRISM -MBC)
This pilot interventional study evaluates the change from baseline to post-intervention in resilience and other patient-reported outcomes for individuals with a recent diagnosis of metastatic breast cancer (MBC) participating in…
- Trial name
- PRISM-MBC (NCT06855654)
- Testing
- Promoting Resilience in Women with Breast Cancer (PRISM)
- Where
- 2 sites in United States
- Volunteers
- 120 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Metastatic Breast Cancer
Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer
The goal of this trial is to determine the activity of erlotinib in a rationally selected population of women with ER-negative, PR-negative, HER2/neu-negative, EGFR-positive breast cancer.
- Trial name
- NCT00597597
- Testing
- Erlotinib
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Rush University Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.